Mohamed Hagras

1-Elmokhayem Eldaem Street
Cairo, C 11884, Egypt

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Design and synthesis of novel thiazolotriazole-sulfonamide hybrids tackling antimicrobial resistance: mechanistic insights into efflux pump inhibitor, gene downregulation, and machine-aided results.

Design and synthesis of novel thiazolotriazole-sulfonamide hybrids tackling antimicrobial resistance: mechanistic insights into efflux pump inhibitor, gene downregulation, and machine-aided results.

Journal: Bioorganic chemistry

Published: May 21, 2026

New Thiadiazole-Benzenesulfonamide Hybrids as Dual B-Raf/VEGFR-2 Inhibitors With Promising Anti-Hepatic Cancer Activity.

New Thiadiazole-Benzenesulfonamide Hybrids as Dual B-Raf/VEGFR-2 Inhibitors With Promising Anti-Hepatic Cancer Activity.

Journal: Chemical biology & drug design

Published: May 23, 2025

Design and synthesis of thiadiazoles as anticancer, apoptotic, and VEGFR-2 inhibitors.

Design and synthesis of thiadiazoles as anticancer, apoptotic, and VEGFR-2 inhibitors.

Journal: Future medicinal chemistry

Published: April 08, 2025

Repurposing the phenylthiazole scaffold with 1,3,4-oxadiazole for selective, potent and well-tolerated antifungal activity.

Repurposing the phenylthiazole scaffold with 1,3,4-oxadiazole for selective, potent and well-tolerated antifungal activity.

Journal: RSC advances

Published: January 21, 2025

Phenylthiazoles with potent & optimum selectivity toward Clostridium difficile.

Phenylthiazoles with potent & optimum selectivity toward Clostridium difficile.

Journal: RSC medicinal chemistry

Published: March 09, 2024

Virtual screening approach for the discovery of selective 5α-reductase type II inhibitors for benign prostatic hyperplasia treatment.

Virtual screening approach for the discovery of selective 5α-reductase type II inhibitors for benign prostatic hyperplasia treatment.

Journal: Future medicinal chemistry

Published: November 13, 2023

Discovery of new VEGFR-2 inhibitors and apoptosis inducer-based thieno[2,3-d]pyrimidine.

Discovery of new VEGFR-2 inhibitors and apoptosis inducer-based thieno[2,3-d]pyrimidine.

Journal: Future medicinal chemistry

Published: November 13, 2023

Novel phenylthiazoles with a tert-butyl moiety: promising antimicrobial activity against multidrug-resistant pathogens with enhanced ADME properties.

Novel phenylthiazoles with a tert-butyl moiety: promising antimicrobial activity against multidrug-resistant pathogens with enhanced ADME properties.

Journal: RSC advances

Published: November 08, 2023

Discovery of new thiazolidine-2,4-dione derivatives as potential VEGFR-2 inhibitors: In vitro and in silico studies.

Discovery of new thiazolidine-2,4-dione derivatives as potential VEGFR-2 inhibitors: In vitro and in silico studies.

Journal: Heliyon

Published: October 06, 2023

New thiazolidine-2,4-diones as potential anticancer agents and apoptotic inducers targeting VEGFR-2 kinase: Design, synthesis, in silico and in vitro studies.

New thiazolidine-2,4-diones as potential anticancer agents and apoptotic inducers targeting VEGFR-2 kinase: Design, synthesis, in silico and in vitro studies.

Journal: Biochimica et biophysica acta. General subjects

Published: July 29, 2023

New thiouracil derivatives as histone deacetylase inhibitors and apoptosis inducers: design, synthesis and anticancer evaluation.

New thiouracil derivatives as histone deacetylase inhibitors and apoptosis inducers: design, synthesis and anticancer evaluation.

Journal: Future medicinal chemistry

Published: July 26, 2023

Naphthylthiazoles: a class of broad-spectrum antifungals.

Naphthylthiazoles: a class of broad-spectrum antifungals.

Journal: RSC medicinal chemistry

Published: July 10, 2023

Showing 1-12 of 36

Last Updated: 09/26/2026